Germline RBBP6 mutations in familial myeloproliferative neoplasms

Blood

Volumn 127, Issue 3, 2016, Pages 362-365

  Harutyunyan, Ashot S ^a   Giambruno, Roberto ^a   Krendl, Christian ^a   Stukalov, Alexey ^a   Klampfl, Thorsten ^a   Berg, Tiina ^a   Chen, Doris ^a   Feenstra, Jelena D Milosevic ^a   Jäger, Roland ^a   Gisslinger, Bettina ^b   Gisslinger, Heinz ^b   Rumi, Elisa ^c   Passamonti, Francesco ^d   Pietra, Daniela ^c   Müller, Andŕe C ^a   Parapatics, Katja ^a   Breitwieser, Florian P ^a   Herrmann, Richard ^e   Colinge, Jacques ^a   Bennett, Keiryn L ^a   Superti Furga, Giulio ^a   Cazzola, Mario ^c   Hammond, Emma ^f   Kralovics, Robert ^a,b   more..

^a ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF PAVIA   (Italy)

^d University Hospital   (Italy)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f MURDOCH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE PREDISPOSITION; FAMILIAL CANCER; FAMILY HISTORY; GENE; GERMLINE MUTATION; HUMAN; LETTER; MYELOPROLIFERATIVE NEOPLASM; PEDIGREE; PRIORITY JOURNAL; RBBP6 GENE; DNA MUTATIONAL ANALYSIS; FAMILY; FEMALE; GENETICS; MALE; MYELOPROLIFERATIVE DISORDERS;

CARRIER PROTEIN; DNA BINDING PROTEIN; RBBP6 PROTEIN, HUMAN;

CARRIER PROTEINS; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; FAMILY; FEMALE; GERM-LINE MUTATION; HUMANS; MALE; MYELOPROLIFERATIVE DISORDERS; PEDIGREE;

EID: 84958205839     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-09-668673     Document Type: Letter

References (25)

1. Kralovics R, Stockton DW, Prchal JT. Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood. 2003;102(10):3793-3796.
2. Rumi E, Passamonti F, Pietra D, et al. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. Cancer. 2006;107(9):2206-2211.
3. Bellanńe-Chantelot C, Chaumarel I, Labopin M, et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood. 2006;108(1):346-352.
4. Landgren O, Goldin LR, Kristinsson SY, Helgadottir EA, Samuelsson J, Björkholm M. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24, 577 first-degree relatives of 11, 039 patients with myeloproliferative neoplasms in Sweden. Blood. 2008;112(6):2199-2204.
5. James C, Ugo V, Le Coúedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037): 1144-1148.
6. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-1790.
7. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7):e270.
8. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379-2390.
9. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013; 369(25):2391-2405.
10. Lundberg P, Nienhold R, Ambrosetti A, Cervantes F, Pérez-Encinas MM, Skoda RC. Somatic mutations in calreticulin can be found in pedigrees with familial predisposition to myeloproliferative neoplasms. Blood. 2014;123(17): 2744-2745.
11. Maffioli M, Genoni A, Caramazza D, et al. Looking for CALR mutations in familial myeloproliferative neoplasms. Leukemia. 2014;28(6):1357-1360.
12. Rumi E, Harutyunyan AS, Pietra D, et al; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis. Blood. 2014;123(15):2416-2419.
13. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360(22):2289-2301.
14. Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363(25):2424-2433.
15. Carbuccia N, Murati A, Trouplin V, et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia. 2009;23(11):2183-2186.
16. Olcaydu D, Rumi E, Harutyunyan A, et al. The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. Haematologica. 2011;96(3):367-374.
17. Saint-Martin C, Leroy G, Delhommeau F, et al; French Group of Familial Myeloproliferative Disorders. Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms. Blood. 2009;114(8):1628-1632.
18. Olcaydu D, Harutyunyan A, Jäger R, et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet. 2009;41(4):450-454.
19. Jäger R, Harutyunyan AS, Rumi E, et al. Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms. Am J Hematol. 2014;89(12):1107-1110.
20. Oddsson A, Kristinsson SY, Helgason H, et al. The germline sequence variant rs2736100°C in TERT associates with myeloproliferative neoplasms. Leukemia. 2014;28(6):1371-1374.
21. Tapper W, Jones AV, Kralovics R, et al. Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. Nat Commun. 2015;6:6691.
22. Li L, Deng B, Xing G, et al. PACT is a negative regulator of p53 and essential for cell growth and embryonic development. Proc Natl Acad Sci USA. 2007; 104(19):7951-7956.
23. Lee WH, Bookstein R, Hong F, Young LJ, Shew JY, Lee EY. Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science. 1987;235(4794):1394-1399.
24. Wallace MR, Marchuk DA, Andersen LB, et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science. 1990;249(4965):181-186.
25. Hussussian CJ, Struewing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. Nat Genet. 1994;8(1):15-21.